Patents by Inventor Madalee G. Wulf
Madalee G. Wulf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912707Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.Type: GrantFiled: March 2, 2021Date of Patent: February 27, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew Kruegel, Dalibor Sames, Madalee G. Wulf, Jonathan A. Javitch
-
Patent number: 11840541Abstract: The present invention provides a compound having the structure wherein A is a ring structure, with or without substitution; X1 is C or N; X2 is N, O, or S; Y1 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 2 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y3 is H-(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 4 is H-(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y5 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); a and P are each present or absent and when present each is a bond.Type: GrantFiled: November 25, 2015Date of Patent: December 12, 2023Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew C. Kruegel, Madalee G. Wulf, Jonathan A. Javitch, Dalibor Sames
-
Publication number: 20230271976Abstract: The present invention provides a compound having the structure wherein A is a ring structure, with or without substitution; X1 is C or N; X2 is N, O, or S; Y1 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), (haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 2 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), (haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y3 is H-(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), (haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 4 is H-(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), (haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y5 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), (haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); a and P are each present or absent and when present each is a bond.Type: ApplicationFiled: April 7, 2023Publication date: August 31, 2023Applicant: The Trustees of Columbia University in the City of New YorkInventors: Andrew C. Kruegel, Madalee G. Wulf, Jonathan A. Javitch, Dalibor Sames
-
Publication number: 20230022745Abstract: A method of labeling, and optionally enriching, for a population of target RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding a label to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated target RNA molecules in a sample by incubating the sample with labeled GTP and a capping enzyme; and (b) optionally enriching for target RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag. The label may be an oligonucleotide, which may further comprise an affinity group attached either internally or at 5? or 3? end of the oligonucleotide where the oligonucleotide label may be added directly, or indirectly via a reaction with a reactive group to the target RNA.Type: ApplicationFiled: September 14, 2022Publication date: January 26, 2023Applicant: New England Biolabs, Inc.Inventors: Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, JR., George Tzertzinis, John Buswell, Madalee G. Wulf
-
Patent number: 11479766Abstract: A method of labeling, and optionally enriching, for a population of target RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding a label to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated target RNA molecules in a sample by incubating the sample with labeled GTP and a capping enzyme; and (b) optionally enriching for target RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag. The label may be an oligonucleotide, which may further comprise an affinity group attached either internally or at 5? or 3? end of the oligonucleotide where the oligonucleotide label may be added directly, or indirectly via a reaction with a reactive group to the target RNA.Type: GrantFiled: February 28, 2018Date of Patent: October 25, 2022Assignee: New England Biolabs, Inc.Inventors: Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, Jr., George Tzertzinis, John Buswell, Madalee G. Wulf
-
Publication number: 20220195424Abstract: Provided herein is a method for chemically capping polynucleotides having a 5? monophosphate. In some embodiments the method may comprise: combining an activated nucleoside 5? mono- or poly-phosphate with a population of polynucleotides that comprises polynucleotides having a 5? monophosphate, to produce a reaction mix; and incubating the reaction mix to produce reaction products that comprise a polynucleotide and a 5? nucleoside cap, linked by a 5? to 5? polyphosphate linkage. The chemical capping method described herein can be incorporated into a variety of cDNA synthesis methods.Type: ApplicationFiled: May 6, 2020Publication date: June 23, 2022Applicant: New England Biolabs, Inc.Inventors: Ivan R. Correa, Jr., Shengxi Guan, Madalee G. Wulf, Nan Dai, Sean Maguire
-
Publication number: 20220106279Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: July 6, 2021Publication date: April 7, 2022Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew C. Kruegel, Adam Henke, Madalee G. Wulf, Marie-Laure Rives, Jonathan A. Javitch, Dalibor Sames
-
Patent number: 11225658Abstract: Provided herein is a method for making an cDNA library, comprising adding an affinity tag-labeled GMP to the 5? end of targeted RNA species in a sample by optionally decapping followed by incubating the sample with an affinity tag-labeled GTP and a capping enzyme, enriching for RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag, reverse transcribing the enriched RNA to produce a population of cDNAs, and adding a tail to the 3? end of the population of cDNAs using a terminal transferase, to produce an cDNA library.Type: GrantFiled: October 17, 2017Date of Patent: January 18, 2022Assignee: New England Biolabs, Inc.Inventors: Bo Yan, Laurence Ettwiller, Ira Schildkraut, George Tzertzinis, Ivan R. Correa, Jr., Nan Dai, Madalee G. Wulf
-
Publication number: 20210179618Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.Type: ApplicationFiled: March 2, 2021Publication date: June 17, 2021Applicant: The Trustees of Columbia University in the City of New YorkInventors: Andrew Kruegel, Dalibor Sames, Madalee G. Wulf, Jonathan A. Javitch
-
Patent number: 10961244Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.Type: GrantFiled: March 24, 2017Date of Patent: March 30, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Andrew Kruegel, Dalibor Sames, Madalee G. Wulf, Jonathan A. Javitch
-
Patent number: 10844027Abstract: The present invention provides a compound having the structure of the instant invention of a pharmaceutically acceptable salt or ester thereof, methods of preparing the same, and methods of treating a subject with compounds of the instant invention in combination therapies.Type: GrantFiled: September 16, 2016Date of Patent: November 24, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew Kruegel, Dalibor Sames, Madalee G. Wulf, Jonathan A. Javitch
-
Publication number: 20190084983Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.Type: ApplicationFiled: March 24, 2017Publication date: March 21, 2019Applicant: The Trustees of Columbia University in the City of New YorkInventors: Andrew Kruegel, Dalibor Sames, Madalee G. Wulf, Jonathan A. Javitch
-
Publication number: 20190047970Abstract: The present invention provides a compound having the structure of the instant invention of a pharmaceutically acceptable salt or ester thereof, methods of preparing the same, and methods of treating a subject with compounds of the instant invention in combination therapies.Type: ApplicationFiled: September 16, 2016Publication date: February 14, 2019Applicant: The Trustees of Columbia University in the City of New YorkInventors: Andrew KRUEGEL, Dalibor SAMES, Madalee G. WULF, Johnathan A. JAVITCH
-
Publication number: 20180195061Abstract: A method of labeling, and optionally enriching, for a population of target RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding a label to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated target RNA molecules in a sample by incubating the sample with labeled GTP and a capping enzyme; and (b) optionally enriching for target RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag. The label may be an oligonucleotide, which may further comprise an affinity group attached either internally or at 5? or 3? end of the oligonucleotide where the oligonucleotide label may be added directly, or indirectly via a reaction with a reactive group to the target RNA.Type: ApplicationFiled: February 28, 2018Publication date: July 12, 2018Applicant: New England Biolabs, Inc.Inventors: Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, Jr., George Tzertzinis, John Buswell, Madalee G. Wulf
-
Publication number: 20180030436Abstract: Provided herein is a method for making an cDNA library, comprising adding an affinity tag-labeled GMP to the 5? end of targeted RNA species in a sample by optionally decapping followed by incubating the sample with an affinity tag-labeled GTP and a capping enzyme, enriching for RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag, reverse transcribing the enriched RNA to produce a population of cDNAs, and adding a tail to the 3? end of the population of cDNAs using a terminal transferase, to produce an cDNA library.Type: ApplicationFiled: October 17, 2017Publication date: February 1, 2018Applicant: New England Biolabs, Inc.Inventors: Bo Yan, Laurence Ettwiller, Ira Schildkraut, George Tzertzinis, Ivan R. Correa, JR., Nan Dai, Madalee G. Wulf